Paul Scrivener is an independent consultant to the Cayman Islands Corporate practice. He is an acknowledged expert in insurance and reinsurance where he has a particular focus on captive insurance. He was formerly a senior partner and head of insurance at another Cayman Islands law firm that he joined as a partner in 1998. Prior to that Paul was a partner with Eversheds in the UK where he handled a wide range of corporate work.
Paul works with a wide array of insurers, reinsurers, captive owners, insurance managers and insurance consultants. His advice includes the formation, restructuring and liquidation of insurance and reinsurance entities and the review or preparation of constitutional documents, shareholder agreements, participation agreements, information memoranda, reinsurance agreements, letters of credit, loss portfolio transfers and commutation agreements. He has particular expertise in relation to cell companies and portfolio insurance companies and has been involved in many insurance mergers and redomestications.
Paul has been a speaker at many international insurance conferences and a regular contributor to industry publications. He has been actively involved in the Cayman insurance sector sitting on various committees including the Cayman Islands Financial Services Legislative Committee, a public/private sector committee tasked with keeping Cayman Islands financial services legislation under review. Paul was instrumental in developing Cayman’s cutting edge Portfolio Insurance Company structure and assisting government with implementing the legislation. He has been consistently ranked for many years by Chambers Global and Legal 500 and has been described by Chambers Global as “an outstanding, extraordinarily responsive lawyer whom clients consider to be approachable, knowledgeable and a pleasure to work with.”
2025年4 月3日
康德明律师事务所荣获四项《商法》2024 年年度杰出交易奖项
2024年11 月23日
基金的年度董事会会议及其他企业管治要求
2024年6 月17日
BVI商事法庭驳回债务人撤销9,700万美元判决的请求
2025年3 月17日
槟杰科达国际有限公司私有化并取消于香港联交所上市
2024年9 月24日
A8 新媒体集团有限公司进行私有化
2023年12 月15日
康德明就朗生医药控股有限公司私有化及后除牌向国泰国际医药生产及销售（中国）有限公司提供法律咨询